Genmab's Darzalex passes second Phase III MM test

Genmab A/S (CSE:GEN) said an interim analysis of the Phase III POLLUX (MMY3003) study showed that Darzalex daratumumab met the primary endpoint of improving progression free survival (PFS) in relapsed or refractory multiple myeloma

Read the full 341 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE